GKOS
Glaukos Corporation
NYSE · Healthcare · Medical - Devices · US
$177.47
−1.60%Jul 29, 2026, 23:26 UTC
Glaukos Corporation reported its second quarter 2026 financial results, posting a net loss of $0.14 per share, which beat the Zacks Consensus Estimate of a loss of $0.28 per share and improved from a loss of $0.24 per share in the same quarter a year ago.
Jul 27, 2026, 11:00 UTC
Glaukos completed patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO MicroShunt in adult patients with primary open-angle glaucoma.
Source: